Genoway News
News
0
Ticker
ALGEN.PA
ISIN
FR0004053510
Genoway Eulerpool News
Genoway Stock News
Genoway is being monitored by journalists and investors worldwide. We gather the latest Genoway news here.
- January 25·Yahoo
Genoway Stock Press Releases
Genoway regularly publishes news on the company's website that are relevant for investors.
- January 25•Genoway
- November 16•Genoway
- September 27•Genoway
- July 19•Genoway
- May 27•Genoway
- May 6•Genoway
- March 30•Genoway
- January 26•Genoway
- January 19•Genoway
- January 5•Genoway
- September 17•Genoway
- July 16•Genoway
- May 19•Genoway
- March 26•Genoway
- February 24•Genoway
- January 28•Genoway
- January 15•Genoway
- January 13•Genoway
- January 7•Genoway
Genoway News 2026
This page contains all current news, analysis and press releases for Genoway stock (ALGEN.PA, ISIN: FR0004053510). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Genoway.
Genoway Stock
Genoway Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs.